Wegovy Perks Sustained for Years; Most Have ‘CKM Syndrome’; New Adrenal Guidelines

One in eight U.S. adults have taken semaglutide (Ozempic, Wegovy) or another GLP-1 agonist, a KFF poll found.

Metabolic benefits of semaglutide for weight loss were sustained for several years, according to findings presented at the European Congress on Obesity. In people with overweight or obesity without diabetes, semaglutide yielded an average 10.2% weight loss and 7.7 cm reduction in waist circumference after 4 years. (Nature Medicine)

Nearly 90% of U.S. adults 20 and older met any level criteria for “CKM syndrome” — a combination of cardiovascular, kidney, and metabolic risks — and 15% met criteria for advanced stages. (JAMA)

Around 25% of people 16 or older with insulin-dependent diabetes had eating disorder symptoms, according to a meta-analysis of 45 studies. (Eating Behaviors)

The Endocrine Society and European Society of Endocrinology released new joint guidelines on glucocorticoid-induced adrenal insufficiency. (Journal of Clinical Endocrinology & Metabolism)

An Australian study found people who were dispensed a GLP-1 receptor agonist were 44% more likely to also be dispensed an antidepressant. (Diabetes, Obesity and Metabolism)

Some women on GLP-1 receptor agonists are becoming pregnant after struggling with infertility. (CNN)

Hilary Cass, OBE, who published a report that led to restrictions on puberty blockers for transgender youth in Britain, said U.S. doctors are “out of date” on youth gender medicine. (New York Times)

Premature menopause was linked with early death in research presented at the annual European Congress of Endocrinology. (Newsweek)

Please enable JavaScript to view the

comments powered by Disqus.